Use of the plasma triglyceride/high-density lipoprotein cholesterol ratio to identify cardiovascular disease in hypertensive subjects

Journal of the American Society of Hypertension

Volumn 8, Issue 10, 2014, Pages 724-731

  Salazar, Martin R ^a,b   Carbajal, Horacio A ^b   Espeche, Walter G ^a,b   Aizpurua, Marcelo ^c   Sisnieguez, Carlos E Leiva ^a,b   Sisnieguez, Betty C Leiva ^a,b   March, Carlos E ^a,b   Stavile, Rodolfo N ^a,b   Balbin, Eduardo ^a   Reaven, Gerald M ^d  

^a Hospital Interzonal General de Agudos de La Plata   (Argentina)

^b UNIVERSIDAD NACIONAL DE LA PLATA   (Argentina)

^c Hospital Municipal de Rauch   (Argentina)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular outcome; hypertension; metabolic syndrome; TG HDL C ratio

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; ARTICLE; CARDIAC PATIENT; CARDIOMETABOLIC RISK; CARDIOVASCULAR RISK; COMPARATIVE STUDY; ESSENTIAL HYPERTENSION; FEMALE; GLUCOSE BLOOD LEVEL; HIGH RISK POPULATION; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL; AGED; BLOOD; CARDIOVASCULAR DISEASES; COMPLICATION; FACTUAL DATABASE; HYPERTENSION; MIDDLE AGED; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; DATABASES, FACTUAL; FEMALE; HUMANS; HYPERTENSION; MALE; METABOLIC SYNDROME X; MIDDLE AGED; RISK FACTORS; TRIGLYCERIDES;

EID: 84923248333     PISSN: 19331711     EISSN: 18787436     Source Type: Journal    
DOI: 10.1016/j.jash.2014.08.002     Document Type: Article

References (26)

1. Lima NKC, Abbasi F, Lamendola C, Reaven GM. Prevalence of insulin resistance and related risk factors for cardiovascular disease in patients with essential hypertension. Am J Hypertens 2009;22:106-11.
2. Sheu WH, Jeng CY, Shieh SM, Fuh MM, Shen DD, Chen YD, et al. Insulin resistance and abnormal electrocardiograms in patients with high blood pressure. Am J Hypertens 1992;5:444-8.
3. Reaven GM. Wanted! A standardized measurement of plasma insulin concentration. Arterioscler Thromb Vasc Biol 2011;31:954-5.
4. Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640-5.
5. Mancia G, Bombelli M, Corrao G, Facchetti R, Madotto F, Giannattasio C, et al. Metabolic syndrome in the Pressioni Arteriose Monitorate E Loro Associa-zioni (PAMELA) study: daily life blood pressure, cardiac damage, and prognosis. Hypertension 2007;49: 40-7.
6. Salazar MR, Carbajal HA, Espeche WG, Leiva Sisnieguez CE, Balbin E, Dulbecco CA, et al. Relation among the plasma triglyceride/high-density lipoprotein cholesterol concentration ratio, insulin resistance, and associated cardio metabolic risk factors in men and women. Am J Cardiol 2012;109:1749-53.
7. Salazar MR, Carbajal HA, Espeche WG, Aizpur ua M, Leiva Sisnieguez CE, March CE, et al. Cardiovascular disease risk and outcome: Use of the plasma triglyceride/high-density lipoprotein cholesterol concentration ratio versus metabolic syndrome criteria. J Int Med 2013;273:595-601.
8. Salazar MR, Carbajal HA, Aizpur ua M, Riondet B, Rodrigo HF, Rechifort V, et al. Decrease of blood pressure by community-based strategies. Medicina (B Aires) 2005;65:507-12.
9. Salazar MR, Carbajal HA, Curciarello JO, Aizpur ua M, Adrover RE, Riondet B. Alanine-aminotransferase: an early marker for insulin resistance? Medicina (B Aires) 2007;67:125-30.
10. Avena SA, Goicoechea AS, Rey J, Dugoujon JM, Dejean CB, Carnese FR. Gene mixture in a population sample from Buenos Aires City. Medicina (B Aires) 2006;66:113-8.
11. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracen-trifuge. Clin Chem 1972;18:499-502.
12. Abbasi F, Okeke Q, Reaven GM. Evaluation of fasting plasma insulin concentration as an estimate of insulin action in nondiabetic individuals: comparison with the homeostasis model assessment of insulin resistance (HOMA-IR). Acta Diabetol 2014;51:193-7.
13. McLaughlin T, Reaven G, Abbasi F, Lamendola C, Saad M, Waters D, et al. Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease? Am J Cardiol 2005;96:399-404.
14. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607.
15. Reaven GM. The insulin resistance syndrome. Curr Atheroscler Rep 2003;5:364-71.
16. Einhorn D, Reaven GM, Cobin RH, Ford E, Ganda OP, Handelsman Y, et al. American College of Endocrinology position statement on the insulin resistant syndrome. Endocr Pract 2003;9:237-52.
17. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F Low triglycerides-high high-density lipoprotein cholesterol and risk of ischemic heart disease. Arch Intern Med 2001;161:361-6.
18. Zavaroni I, Bonini L, Gasparini P, Barilli AL, Zuccarelli A, Dall'Aglio E, et al. Hyperinsulinemia in a normal population as a predictor of non-insulin-dependent diabetes mellitus, hypertension, and coronary heart disease: The Barilla factory revisited. Metabolism 1999;48:989-94.
19. Murguia-Romero M, Jimenez-Flores JR, Sigrist-Flores SC, Espinoza-Camacho MA, Jimenez-Morales M, Pina E, et al. Plasma triglyceride/high-density lipoprotein cholesterol ratio, insulin resistance, and cardio-metabolic risk in young men and women. J Lipid Res 2013;54: 2795-9.
20. Chu JW, Abbasi F, Kulkarni K, Lamendola C, McLaughlin TL, Scalisi JN, et al. Multiple lipoprotein abnormalities associated with insulin resistance in healthy volunteers are identified by the Vertical Auto Profile-II methodology. Clin Chem 2003;49:1014-7.
21. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA 2010;303:2043-50.
22. Muntner P, Levitan EB, Reynolds K, Mann DM, Tonelli M, Oparil S, et al. Within-visit variability of blood pressure and all-cause and cardiovascular mortality among US adults. J Clin Hypertens (Greenwich) 2012;14:165-71.
23. Handler J, Zhao Y, Egan BM. Impact of the number of blood pressure measurements on blood pressure classification in US adults: NHANES 1999-2008. J Clin Hypertens (Greenwich) 2012;14:751-9.
24. Shin JH, Shin J, Kim BK, Lim YH, Park HC, Choi SI, et al. Within-visit blood pressure variability: relevant factors in the general population. J Hum Hypertens 2013;27:328-34.
25. Wofford MR, King DS, Wyatt SB, Jones DW. Secondary hypertension: detection and management for the primary care provider. J Clin Hypertens (Greenwich) 2000;2:124-31.
26. Omura M, Saito J, Yamaguchi K, Kakuta Y, Nishikawa T. Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in japan. Hypertens Res 2004;27:193-202.